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Re: Possible Role of Ovarian
Epithelial Inflammation in
Ovarian Cancer
In the September 1, 1999, issue of the
Journal, Ness and Cottreau (1) discuss
the role of inflammation in the patho-
genesis of ovarian cancer. In reviewing
the current literature, they conclude that
neither incessant ovulation nor gonado-
tropin stimulation provides a completely
satisfactory explanation for the genesis
of ovarian cancer. They suggest that
ovarian inflammation, with rapid DNA
turnover, oxidative stress, and increased
cytokine production, may be an impor-
tant contributor to the development of
ovarian malignancies.
For the past 10 years, we have been
studying the role of cytokines in human
ovarian cancer biology. We have found
that the cytokine network in this tumor
is rich in proinflammatory cytokines,
growth factors, and chemokines (2–4).
Our experiments to date suggest that
the proinflammatory cytokine tumour
necrosis factor-a (TNF-a) is central to
this ovarian cancer microenvironment.
TNF-a is expressed in the epithelial tu-
mor islands of ovarian cancer biopsy
specimens (the level of expression in-
creasing with tumor grade) and is impli-
cated in the process of ovarian cancer
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stromal development and regulation of
chemokines and matrix metalloprote-
ases [(2–6) and references therein]. We
also carried out tumor induction experi-
ments in TNF-a deficient mice and
found that these mice are resistant to
skin carcinogenesis (7). This result pro-
vides direct evidence that a proinflam-
matory cytokine is required for de novo
carcinogenesis and that TNF-a is impor-
tant to the early stages of epithelial tu-
mor promotion.
The role of TNF-a in promoting the
development of tumor stroma and con-
trolling host and tumor interactions ap-
pears to be analogous to its action in
inflammatory disease. At some stages of
inflammation, TNF-a can cause tissue
destruction and necrosis. Similarly, high
doses of TNF-a delivered locally to the
tumor site cause disruption of the tumor
vasculature followed by necrosis. How-
ever, lower doses of endogenous TNF-a
in the inflammatory microenvironment
can promote tissue repair via induction
of chemokines and stimulation of fibro-
blasts and neovasculature. The actions
of endogenous TNF-a in cancer are
similar, except that TNF-a produced
chronically in the tumor does not lead to
resolution of the lesion.
Thus, inflammatory cytokines in the
tumor microenvironment may not con-
tribute to the genetic damage that ini-
tiates the cancer but they may be “a fuel
that fans the flames.”
Finally, it is possible that inflamma-
tory cytokines are important to the evo-
lution of many different malignancies
and not just epithelial ovarian cancer.
FRANCES R. BALKWILL
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RESPONSE
We appreciate Dr. Balkwill’s letter
expanding upon our discussion of the
role of inflammation in the pathogenesis
of ovarian cancer (1). Dr. Balkwill
presents a synopsis of data suggesting
that cytokines are one type of inflamma-
tory mediator that may potentially initi-
ate or promote ovarian cancer. We have
also hypothesized that other mecha-
nisms that come into play in the inflam-
matory process, including rapid DNA
turnover, oxidative stress, and prosta-
glandins, may play some role in ovarian
cancer development. We certainly agree
that these mechanisms are not uniquely
related to ovarian cancer. Indeed, our
hypothesis drew on the thinking by
Ames et al. (2), who suggested that in-
flammation underlies carcinogenesis in
general. Our paper provided specific
epidemiologic and some basic biologic
support for a relationship between in-
flammation and ovarian carcinogenesis.
The presence of cytokines, e.g., tu-
mor necrosis factor-a (TNF-a) in al-
ready developed ovarian tumors cannot
be taken as evidence that cytokines
cause ovarian tumors, since tumor de-
velopment almost surely results in an in-
flammatory response. However, the fact
that mice deficient in TNF-a do not de-
velop skin cancers suggests that, at least
for that tumor type, cytokines are impor-
tant factors in carcinogenesis. We do not
believe that any of the experiments to
which Dr. Balkwill refers can clearly
distinguish between tumor initiation and
tumor promotion. Nor does this body of
evidence preclude a role for oxidation,
genetic damage, etc., in tumor initiation.
However, Dr. Balkwill’s experiments
add fuel to our fire and support our call
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